Depression and Inflammation in Women with Breast Cancer: Risk and Resilience Factors

By sjmartinez • May 14, 2025

Korecki JRT, Slavich GM, Ganz PA, Irwin MR, Cole S, Crespi CM, Bower JE. Depression and Inflammation in Women with Breast Cancer: Risk and Resilience Factors. Biopsychosoc Sci Med. 2025 May 9. doi: 10.1097/PSY.0000000000001398. Epub ahead of print. PMID: 40359350.

Tags: and Energy study, BMI, body mass index, breast cancer survivors, C-reactive protein, CBT-I, Center for Epidemiological Studies Depression Scale, CES-D, CI, cognitive behavioral therapy for insomnia, confidence interval, CRP, depression, Hematology/Oncology, IL-6, Inflammation, interleukin, Life Orientation Test-Revised, lifetime stressor exposure, LOT-R, PA, physical activity, Pittsburgh Sleep Quality Index, PSQI, Publications, Research on Inflammation, resilience, RISE, SD, standard deviation, Strain, Stress, Stress and Adversity Inventory, TNF-α, Tumor necrosis factor-α

Related Posts

US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan

Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney[...]

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

Melisi D, Macarulla T, De La Fouchardière C, Pazo Cid RA, Chandana SR, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab[...]

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study

Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi[...]